Amundi 13F: Adds $56M to AbbVie (ABBV) Stake

Amundi Expands Position in AbbVie

Institutional investor Amundi expanded its position in AbbVie Inc. (NYSE:ABBV) during the period, lifting its holdings by 2.4%. According to its most recent Form 13F filing with the Securities and Exchange Commission, the firm added 247,689 shares of the drug maker to its portfolio. The trade brought Amundi's total ownership to 10,698,095 shares. Based on the report, the massive stake carried a value of about $2.42 billion.

What Changed in the Holding

Prior to the filing, Amundi held 10,450,406 shares of AbbVie. The addition of 247,689 shares represents a 2.4% increase in the fund's position. Because Form 13F filings look backward at past quarters, these holdings reflect portfolio weights as of the reporting date and may not represent the investor's current position today.

AbbVie Stock Performance

Shares of AbbVie trade near $226.28 on the New York Stock Exchange. The company carries a forward P/E ratio of 16.3 and has seen steady interest from large asset managers. The stock's 52-week trading range spans from a low of $190.75 up to a high of $267.47, keeping it comfortably placed in the middle of its yearly channel.

Recent Analyst Ratings

Wall Street firms continue to maintain generally positive outlooks on the pharmaceutical giant. On October 13, 2026, RBC Capital reiterated its Outperform rating with a $280.00 price target. Earlier in October, UBS maintained its Neutral stance while raising its target from $260.00 to $275.00 on October 9, 2026. Guggenheim reiterated its Buy rating with a $288.00 target on October 9, 2026, and JP Morgan maintained an Overweight rating while lifting its target from $285.00 to $300.00 on October 8, 2026.

Additional updates came on October 8, 2026, when Cantor Fitzgerald maintained an Overweight rating and bumped its target to $290.00 from $285.00. Morgan Stanley kept an Overweight rating with a $310.00 target on October 7, 2026. Scotiabank maintained a Sector Outperform rating on October 6, 2026, raising its price target to $320.00 from $280.00, and HSBC maintained a Buy rating with a $315.00 target on September 10, 2026.

About AbbVie Inc.

Headquartered in North Chicago, Illinois, AbbVie is a research-based biopharmaceutical company that develops and sells treatments across immunology, oncology, and neuroscience. Its key products include autoimmune therapies Skyrizi and Rinvoq, blood cancer drugs Imbruvica and Venclexta, and the Botox cosmetic and therapeutic product lines. The company employs roughly 57,000 people worldwide.

What's Ahead for ABBV

Investors tracking Amundi's moves will want to watch for future SEC disclosures to see how the firm adjusts its healthcare weightings. AbbVie's next quarterly financial results are scheduled for release on October 29, 2026. Because 13F data is historical, it offers a snapshot of past institutional shifts rather than real-time trading activity.